Drug Profile
TQ B3101
Alternative Names: TQ-B3101Latest Information Update: 12 Jan 2023
Price :
$50
*
At a glance
- Originator Chia Tai Tianqing Pharmaceutical Group
- Class Antineoplastics; Small molecules
- Mechanism of Action Anaplastic lymphoma kinase inhibitors; Proto-oncogene protein c-met inhibitors; ROS1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Anaplastic large cell lymphoma; Non-small cell lung cancer
- No development reported Solid tumours
Most Recent Events
- 11 Dec 2022 Efficacy, safety and pharmacokinetics data from the phase II TQ-B3101-II-02 trial in Anaplastic large cell lymphoma presented at the 64th American Society of Hematology Annual Meeting and Exposition (ASH-2022)
- 28 Sep 2022 Phase II development in Anaplastic large cell lymphoma (Late-stage disease, Second-line therapy or greater, In children, In adolescents, Refractory metastatic disease)is ongoing in China (PO) (NCT04306887)
- 28 Sep 2022 No development reported - Phase-II for Solid tumours (Late-stage disease) in China (PO) (NCT04412564)